Rutuja Shinde’s Post

November is #LungCancerAwarenessMonth – an important milestone to come together and advocate for better outcomes for the patient community. This year, I’m shining a spotlight on the power of biomarker testing in transforming lung cancer care across Europe. Biomarker technologies are revolutionizing how we diagnose and manage lung cancer. By improving our understanding of genetics and offering critical insights into cancer mechanisms, this powerful diagnostic tool has enabled a more personalized approach to lung cancer care, reducing unnecessary treatments and improving patient outcomes through targeted therapies. Yet, while we are seeing a positive shift, with biomarker testing being integrated into diagnostic pathways in cancer centres around the world, there is still significant variation in access to this innovation across different regions – impacting outcomes for patients. Working together as a community to address these disparities can help to make early, precise, and informed diagnosis a reality for everyone impacted by lung cancer. So, let’s continue to spread awareness and champion the value of biomarker testing this #LCAM, and beyond. #LCAM2024 #BiomarkerTesting #NGS #LungCancerCare #InnovationInHealth

The History of Immunotherapy: A Journey of Innovation and Discovery 🛤️ Immunotherapy has transformed our approach to cancer treatment, harnessing the power of the immune system to fight tumors. From the first revolutionary discoveries to the most recent advances, this medical discipline continues to evolve and push back the frontiers of science and medicine. At Innate Pharma, we celebrate the pioneers whose work paved the way for innovative and effective therapies. Their dedication and discoveries have saved lives and given hope to millions of patients around the world 🔬 We are determined to continue this legacy of innovation and explore new avenues to further improve cancer treatments. Together, we are building a future where the immune system will be our best ally in the fight against this disease. To find out more about the latest advances in immunotherapy and join the conversation with experts in the field, don't miss our symposium: https://lnkd.in/eP6QYm8a #InnatePharma #Immunotherapy #Innovation

🔬💼 Exploring the Leading Diseases in US Clinical Development! 💼🔬 In the United States, the forefront of clinical development is predominantly shaped by cancer indications, with non-small cell lung cancer taking the lead, surpassing breast cancer to claim the top spot. 🏥 Interestingly, among the top 10 diseases, two non-cancer indications stand out: Alzheimer’s disease, ranking sixth with 236 drugs in development, surpassing global figures, and the novel coronavirus, ranking ninth with 224 drugs in development, slightly lower than the global count. 🧠🦠 It's noteworthy that the top 10 diseases in US development closely mirror the global landscape, with the exception of acute myelogenous leukemia entering the US list, displacing liver cancer from the global ranking. 🌎 As we navigate these trends, let's harness the power of innovation and collaboration to address the pressing healthcare challenges of our time. Together, we can drive meaningful progress and impact! 💪💊 #ClinicalDevelopment #citeline #alzheimersDisease #alzheimer's #cancer #oncology #clinicaltrials

Evexia Webinar Series: EPISeek - Multi-Cancer Early Detection Screening with Liquid Biopsy Cancer is soon expected to surpass heart disease as the number one cause of mortality. This year, in the USA alone, more than 2 million new cancer diagnoses are expected and more than 610,000 will die from cancer. Globally more than 20 million new cancer diagnoses and nearly 10 million deaths are expected this year. While enormous progress is being made in the treatment of advanced cancer, the most effective approach to better outcomes may be earlier detection of cancers. Compared to early diagnosis (Stages I and II) which can be cured completely with excision, delayed diagnosis (Stage IV) is associated with very poor outcomes and very expensive treatment options. This webinar will explore how precision epigenomics has created an assay that detects abnormally methylated circulating tumor DNA using a simple blood draw. The EPISEEK assay with its patented probes and proprietary classifier can detect the most aggressive cancers with high sensitivity and specificity. Speaker Name and Credentials: Richard A. Bernert, M.D. Register now >> https://lnkd.in/giWjz4sW #MedicalPracticeSuccess #functionalmedicine #integrativemedicine #EvexiaWebinar #EPISeek #MultiCancerDetection #LiquidBiopsy #CancerAwareness #EarlyDetection #PrecisionMedicine #Epigenomics #CancerResearch #HealthcareInnovation #Oncology #FightCancer #CancerScreening #BloodTest #HealthTech #MedicalWebinar #RichardABernert #CancerSurvival #CancerPrevention #Methylation #HealthEducation

Do you want your patients to know more about how biomarker testing is impacting their treatment and clinical trial options? Happy to share this new Biomarker Testing Discussion Guide. Developed in close collaboration between LUNGevity Foundation, patients and providers of different cancer experiences and expertise, this guide can help patients better understand their biomarker testing results. Proud to have represented Foundation Medicine in helping develop this guide. Click here to learn more and review this new guide: https://lnkd.in/e-Td7ncc

Enhance Early Lung Cancer Diagnosis with #Tellgen At Tellgen, we're committed to advancing lung cancer diagnostics with our product, #LUNGME. This molecular diagnostic kit assists in the early diagnosis of lung cancer using molecular realtime fluorescent #PCR methodology. LUNGME targets the genes #SHOX2 & #RASSF1A, enabling differentiation between benign and malignant lung lesions. ✅ Dual-Gene Detection: Provides more objective, specific, and sensitive results. ✅ Multiple Sample Types: Capable of testing bronchoalveolar lavage fluid, sputum, pleural effusion, and biopsy samples. ✅ Versatile applications: suitable for both health checkups and clinical use Early diagnosis of lung cancer significantly improves treatment outcomes and survival rates. By detecting lung cancer at an early stage, patients have access to a wider range of treatment options and a better prognosis. Join us at Tellgen in making a difference in early lung cancer detection. For more information, feel free to contact us at sales@tellgen.com. Welcome your inquiries! #LungCancer #LungCancerDiagnositic #EarlyDiagnosis #MolecularDiagnostics #Tellgen #LUNGME #HealthcareInnovation

🗓️ Event: Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests: A Workshop 📅 Date: October 28 - 29, 2024 🏛️ Hosted by: National Academy of Sciences 🔬 Join them to explore the future of cancer screening! Cancer screening is a crucial strategy for early diagnosis, leading to better treatment options and improved health outcomes. However, most cancers still lack effective screening tests. Multicancer detection (MCD) tests could revolutionize this field by screening for multiple tumor types with minimally invasive approaches. However, the clinical utility of MCD testing is still being established. This workshop will delve into the current state of MCD testing, featuring: - Current and emerging MCD tests - Challenges and opportunities for validating MCDs - Strategies for follow-up diagnostics and treatment decisions - Limitations of MCDs, including false positives and overdiagnosis - Research and policy gaps in MCD assessment and their impact on cancer care and health equity Don't miss out on this opportunity to learn and contribute to the future of cancer screening. Register here https://lnkd.in/e8Bri7HN

🚀 Latest publication from Pedro Fonte’s group on pioneering approaches in cancer treatment! 🚀 In our new paper, "Transforming Cancer Treatment: The Potential of Nanonutraceuticals," we explore the potential of nanonutraceuticals to overcome traditional chemotherapy challenges and bring targeted, more effective treatment options to cancer patients. 💊 Nanonutraceuticals: Offering enhanced solubility, stability, and targeted delivery to improve bioavailability and precision in treatment. 🎯 Targeted Therapy: Ligand-coupled nanocarriers enable nutraceuticals to directly reach cancer cells, minimizing off-target effects. ⚖️ Synergistic Treatment: Co-administration with chemotherapeutic drugs in nanocarriers amplifies therapeutic impact. 📑 From Research to Practice: Covering patents and clinical trials advancing nanonutraceuticals toward practical cancer therapies. Special thanks to my amazing co-authors for their commitment: @Girish Kumar, @Tarun Virmani, @Vaishnavi Chhabra, @Reshu Virmani, @Kamla Pathak, @Sayeed Akhtar, @Mulazim Hussain Asim, @Shumaila Arshad, @Farzana Siddique, and Pedro Fonte. 🔗 Read the full article here: https://lnkd.in/dCh-7Z6X #CancerResearch #Nanonutraceuticals #InnovativeTherapy #TargetedTreatment #Bioavailability #Nanotechnology

🚀 Exciting Growth in the Global Next-Generation Breast Cancer Diagnostic and Screening Market! 🚀 The Global Next Generation Innovations (NextGENi) Breast Cancer Diagnostic and Screening Market was valued at an impressive USD 2.90 billion in 2022 and is expected to grow at a remarkable CAGR of 10.30% through 2028! Next-generation breast cancer diagnostic methods are reshaping the landscape with cutting-edge technologies, molecular insights, and personalized approaches, enabling: ✅ Early and accurate detection ✅ Molecular subtyping based on genetic markers ✅ Better treatment strategies Download report in PDF with chart and figures - https://lnkd.in/gf8ab_84 Report Description - https://lnkd.in/geqfuZgP 🌍 North America leads the way in this market, driven by its advanced healthcare infrastructure and early adoption of Next-Generation Sequencing (NGS). The region’s research institutions and biotech companies are at the forefront of innovation, developing breakthrough technologies that are transforming breast cancer diagnosis. Here are some key players driving this transformation: Abbott Bio-Rad Laboratories, Inc. Hoffmann-La Roche Ltd. Thermo Fisher Scientific Inc. The rising global incidence of breast cancer underscores the urgent need for advanced screening methods that can help detect and treat the disease earlier, saving countless lives. #BreastCancerAwareness #MedicalInnovation #HealthcareTech #NGS #CancerDiagnostics #LifeSciences #HealthcareInnovation #NextGenTech #BreastCancer #Diagnostics #MarketGrowth

November is Lung Cancer Awareness Month. Lung cancer remains the leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) being the most common subtype. Early detection and prompt therapy decisions are crucial in improving patient outcomes. Biomarker testing plays a vital role in guiding these decisions, especially when results are available prior to first-line therapy. IDYLLA™ FIRST by Biocartis enables fast, reliable testing for EGFR, ALK, ROS1, RET, and METex14 in just 3 hours. By identifying actionable biomarkers, it helps healthcare providers initiate the right targeted therapy for over 90% of patients, improving survival chances from the start. Let's continue to raise awareness and take action towards better outcomes for lung cancer patients. For any inquiries, please contact us at sales.sg@spdscientific.com. Visit our website at biomediaholdings.com #LungCancerAwarenessMonth #EarlyDiagnosis #InnovationInHealthcare #MolecularDiagnostics #Biocartis #IDYLLA #LungCancerAwareness #PrecisionMedicine